Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Cough, Idiopathic Pulmonary Fibrosis

In brief

ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.

Key facts

Study ID
NCT05185089
Run by
Nerre Therapeutics Ltd.
People needed
80
Starts
2022-08-01
Expected to finish
2024-06-19
Last updated by the study team
2025-11-10

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.